IGFBP3 (GGG mutant)

IGFBP3 (GGG mutant), also known as IGFBP3-I56G/L80G/L81G, is a research-stage recombinant mutant protein derived from human insulin-like growth factor binding protein 3 (IGFBP-3). This variant contains triple glycine substitutions at amino acid positions 56, 80, and 81, which effectively abolish its ability to bind insulin-like growth factors (IGF-I and IGF-II). Despite the loss of IGF binding, the GGG mutant retains IGF-independent biological activities, including the modulation of epithelial-to-mesenchymal transition (EMT) and the suppression of downstream signaling pathways such as Erk1/2 and Egr-1. In preclinical models of esophageal cancer, the GGG mutant has been shown to promote EMT and invasive growth, suggesting that IGFBP-3 can facilitate tumor progression through mechanisms independent of IGF signaling. The molecule was developed through academic research at institutions including the University of Pennsylvania, supported by NIH and Department of Defense grants.

Other names

IGFBP3-I56G/L80G/L81GGGG-IGFBP3GGG-IGFBP-3GGG-IGFBP 3GGG-mutant IGFBP3I56G/L80G/L81G mutant insulin-like growth factor binding protein-3